NKGen presented new clinical data on troculeucel’s potential in Alzheimer’s, Parkinson’s and frontotemporal dementia.
NKGen Biotech had a slot at a biologics conference in Incheon last week, and the subject was dementia, not cancer, which is a little odd since NKGen actually built its business on cancer-fighting immune cells.
Chairman and CEO Dr Paul Y Song presented the company’s lead program, troculeucel, at Biologics Manufacturing Korea 2026, 17–18 September [1].
Troculeucel is grown from a patient’s own blood. Pull some out, expand the natural killer cells in a lab, send them back in. NK cells are usually cast as tumor killers, hunting down abnormal cells the way ordinary antibodies can’t always manage. NKGen has spent years testing something stranger: whether those same cells, aimed at a different target, might calm the inflammation that seems to gnaw at an aging brain long before a diagnosis ever shows up.
The name changed recently, too. The World Health Organization (WHO) now calls the drug Troculeucel, though the trial paperwork used to list it as SNK01. A small detail, maybe, but a single recognized name tends to matter once a company starts filing with regulators in more than one country at a time.
Song’s presentation covers how troculeucel affects inflammatory markers and abnormal proteins in cerebrospinal fluid (the fluid surrounding the brain and spine, which often carries early chemical signs of disease before any cognitive test picks up on it), along with clinical experience treating Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia. Part of the talk is devoted to Asia’s regulatory landscape, which could give NKGen a faster lane toward an initial approval than the more congested US pathway.
Why present this at a manufacturing conference rather than a medical one? Cell therapy is notoriously hard to produce at real scale, and the room in Incheon is full of people who decide whether a promising lab result ever becomes something a hospital can actually order. That’s a different audience than a room of neurologists, and NKGen seems to know it.
Cognitive decline doesn’t usually get filed under “longevity.” It should. Living longer only helps if the extra years come with a working memory attached, and current Alzheimer’s treatments, most of them built around clearing amyloid plaques from the brain, have had a mixed record at best on that front. An immune-cell approach, if it works the way NKGen thinks it might, would be a genuinely different bet than another plaque-clearing antibody.
NKGen said it would post the Incheon presentation to its Scientific Publications page shortly, alongside data it has already disclosed on troculeucel in neurodegenerative disease [2]. None of that changes where things stand today. NKGen has no approved product, and troculeucel remains investigational, full stop. But it’s worth keeping an eye on. If natural killer cells really can quiet brain inflammation the way the company is betting, it wouldn’t just be one more drug candidate in a crowded pipeline. It would be a different theory of what’s actually causing the damage.
[1] https://nkgenbiotech.com/nkgen-biotech-to-present-on-potential-of-troculeucel-in-neurodegenerative-diseases-at-biologics-manufacturing-korea-2026/
[2] https://link.springer.com/article/10.1186/s13195-025-01681-2
